[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345001-105":59,"doc-detail-345001-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","synthetic-lethality-between-rb-loss-and-e2f3-inhibition-in-small-cell-cancers-targeted-by-pyrimidine-synthesis-blockade","Synthetic lethality between RB-loss and E2F3 inhibition in small cell cancers targeted by pyrimidine synthesis blockade","","Synthetic lethality links E2F3 inactivation to RB-deficient small cell cancer dependency, where E2F3 inhibition restrains cell-cycle progression, proliferation, and tumor growth. E2F3 dependency is shared across RB-inactivated small cell cancers arising from multiple tissues. Blocking de novo pyrimidine synthesis reduces E2F3 expression and suppresses tumor cell proliferation in culture. Leveraging the pan-cancer consequence of RB loss via indirect E2F3 targeting through pyrimidine synthesis inhibition offers a practical treatment strategy.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/synthetic-lethality-between-rb-loss-and-e2f3-inhibition-in-small-cell-cancers-targeted-by-pyrimidine-synthesis-blockade/345001/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/synthetic-lethality-between-rb-loss-and-e2f3-inhibition-in-small-cell-cancers-targeted-by-pyrimidine-synthesis-blockade/345001.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What mechanism connects E2F3 dependency with RB loss in small cell cancers?","Question",{"text":113,"@type":114},"E2F3 dependency is linked to RB inactivation, which occurs nearly universally across small cell cancers. In RB-deficient cancer cells, E2F3 inhibition suppresses cell-cycle progression, proliferation, and in vivo tumor growth.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does de novo pyrimidine synthesis blockade affect E2F3 and tumor proliferation?",{"text":118,"@type":114},"Inhibition of de novo pyrimidine synthesis limits E2F3 expression. This suppression reduces small cell carcinoma proliferation in culture and supports a treatment strategy targeting E2F3 indirectly.",{"name":120,"@type":111,"acceptedAnswer":121},"Why were new cell models generated for nonpulmonary small cell cancer?",{"text":122,"@type":114},"Gene dependency data for nonpulmonary small cell cancer are scarce because there are limited representative models. The work addressed this by establishing cell lines that recapitulate transcriptional and phenotypic features of human small cell neuroendocrine prostate cancer (SCPC).","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},345001,1790909172,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","RESEARCH ARTICLE  \nCELL BIOLOGY  \n OPEN ACCESS  \nSynthetic lethality between RB-loss and E2F3 inhibition in small cell cancers targeted by pyrimidine synthesis blockade  \nEvan R. Abta,b,1,2, Liang Wangc,1, Grigor Varuzhanyanc, Jack Freelanda, Tian Hea, Guadalupe M. Peña-Garciac, Lauryn Rueggd,e, Jami McLaughlinc, Donghui Chengc, Nikolas G. Balanisa, Chia-Chun Chenc, Yang Xuf,g,h, Yi Xingg,h,i, Sanaz Memarzadeha,b,d,e,j,k, Caius G. Radua,b , Thomas G. Graebera,b,l,m,n, and Owen N. Wittea,b,c,e,k,o,2  \nAffiliations are included on p. 10.  \nContributed by Owen N. Witte; received November 14, 2025; accepted February 6, 2026; reviewed by Arul M. Chinnaiyan, Charles M. Rudin, and Julien Sage  \nSmall cell carcinoma is a highly lethal cancer variant often found with neuroendocrine (NE) features, as exemplified by small cell lung cancer and small cell NE prostate cancer (SCPC). A genome-wide CRISPR dependency screen using SCPC models generated through human prostate cell transformation identifies a requirement for the transcription factor E2F3. E2F3 dependency is linked to RB inactivation, a near universal occurrence across small cell cancers. The requirement for E2F3 is shared by RB-deficient cells originating from the prostate, lung, and adnexa. In RB-deficient cancer cells, E2F3 inhibition restrains cell cycle progression, proliferation, and tumor growth in vivo. Inhibition of de novo pyrimidine synthesis limits E2F3 expression and suppresses small cell carcinoma proliferation in culture. Directly or indirectly targeting E2F3 to leverage a pan-cancer synthetic lethality resulting from RB inactivation represents a potential treatment strategy.  \nRB tumor suppressor | small cell cancer | synthetic lethality | nucleotide metabolism  \nSmall cell cancers are aggressive malignancies frequently characterized by neuroendocrine (NE) features that arise in multiple tissues such as the lung ( 1), prostate (2), bladder (3), adnexa (4), and colon (5). Small cell cancer develops either de novo or via trans-differentiation from adenocarcinoma as a mechanism of resistance to targeted therapies. The incidence of treatment-driven small cell cancer transformation is increasing and is a mechanism of escape from androgen-deprivation therapy in prostate cancer (6) and EGFR inhibition in lung cancer (7, 8) . The chemotherapy regimens that are transiently effective for the treatment of small cell lung cancer (SCLC) are also administered for nonpulmonary small cell cancers due to their similar histology and molecular characteristics, but they are generally less effective in these settings (9) .  \nThe dismal prognosis of patients with small cell cancers is in part due to a complete lack of treatment options that leverage knowledge of the genetic alterations that drive the disease. Small cell cancers maintain tissue-specific genetic features ( 10, 11) but converge at histological, transcriptional, genetic, and epigenetic levels ( 12–14) . Inactivation of RBand TP53 occurs nearly universally across small cell cancers (15, 16) and loss of these tumor suppressors is a key event in the small cell NE transdifferentiation of prostate (17), lung ( 18), and bladder cells ( 10).The ubiquitous genetic alterations that are shared by small cell cancers may give rise to common vulnerabilities amenable to therapeutic targeting.  \nThe Cancer Dependency Map (DepMap) project defined the landscape of genetic dependencies across cancer cell lines using CRISPR knockout (KO) and shRNA screens (19). While such data are available for over 25 SCLC cell lines, gene dependency data for nonpulmonary small cell cancer is scarce due to a limited number of representative models. NCI-H660 is the only small cell prostate cancer cell line profiled in DepMap, and small cell cancers derived from other tissue types, such as the bladder, have no DepMap-indexed cell lines.  \nTo address this gap, we established a series of cell lines that recapitulate the transcriptional and phenotypic characteris","cbCaivx3UanW2yuu","https://ap.wps.com/l/cbCaivx3UanW2yuu","pdf",8162208,"English","# Background and rationale\n## E2F3 dependency and RB inactivation in small cell cancers\n## Limitations of existing dependency data\n# Model development and experimental approach\n## SCPC recapitulation using transformed prostate basal cells\n# Findings and significance\n## Therapeutic implications of pyrimidine synthesis blockade","[{\"question\":\"What mechanism connects E2F3 dependency with RB loss in small cell cancers?\",\"answer\":\"E2F3 dependency is linked to RB inactivation, which occurs nearly universally across small cell cancers. In RB-deficient cancer cells, E2F3 inhibition suppresses cell-cycle progression, proliferation, and in vivo tumor growth.\"},{\"question\":\"How does de novo pyrimidine synthesis blockade affect E2F3 and tumor proliferation?\",\"answer\":\"Inhibition of de novo pyrimidine synthesis limits E2F3 expression. This suppression reduces small cell carcinoma proliferation in culture and supports a treatment strategy targeting E2F3 indirectly.\"},{\"question\":\"Why were new cell models generated for nonpulmonary small cell cancer?\",\"answer\":\"Gene dependency data for nonpulmonary small cell cancer are scarce because there are limited representative models. The work addressed this by establishing cell lines that recapitulate transcriptional and phenotypic features of human small cell neuroendocrine prostate cancer (SCPC).\"}]","Synthetic lethality between RB-loss and E2F3 inhibition in small cell cancers targeted by pyrimidine synthesis blockade | PDF",1790056137,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8e330f5d526c29893d2b8e6eff0bd7fc.webp",983,1316,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7366a22b3168ab4e1bae0db01f2ad51b.webp",982,1315,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/296c3afba90facc1854d43c051396201.webp",981,1313,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4205a7b3ae50383b81c124ed01622b25.webp",980,1312]